全文获取类型
收费全文 | 29331篇 |
免费 | 1426篇 |
国内免费 | 195篇 |
专业分类
耳鼻咽喉 | 320篇 |
儿科学 | 545篇 |
妇产科学 | 703篇 |
基础医学 | 3401篇 |
口腔科学 | 1522篇 |
临床医学 | 2232篇 |
内科学 | 7942篇 |
皮肤病学 | 443篇 |
神经病学 | 2723篇 |
特种医学 | 1111篇 |
外科学 | 4232篇 |
综合类 | 112篇 |
一般理论 | 7篇 |
预防医学 | 1540篇 |
眼科学 | 432篇 |
药学 | 1628篇 |
中国医学 | 118篇 |
肿瘤学 | 1941篇 |
出版年
2023年 | 162篇 |
2022年 | 329篇 |
2021年 | 803篇 |
2020年 | 457篇 |
2019年 | 632篇 |
2018年 | 819篇 |
2017年 | 574篇 |
2016年 | 698篇 |
2015年 | 804篇 |
2014年 | 1106篇 |
2013年 | 1492篇 |
2012年 | 2278篇 |
2011年 | 2446篇 |
2010年 | 1407篇 |
2009年 | 1247篇 |
2008年 | 2125篇 |
2007年 | 2180篇 |
2006年 | 2008篇 |
2005年 | 2023篇 |
2004年 | 1799篇 |
2003年 | 1554篇 |
2002年 | 1446篇 |
2001年 | 188篇 |
2000年 | 121篇 |
1999年 | 169篇 |
1998年 | 240篇 |
1997年 | 190篇 |
1996年 | 186篇 |
1995年 | 146篇 |
1994年 | 136篇 |
1993年 | 91篇 |
1992年 | 101篇 |
1991年 | 91篇 |
1990年 | 74篇 |
1989年 | 80篇 |
1988年 | 74篇 |
1987年 | 52篇 |
1986年 | 53篇 |
1985年 | 46篇 |
1984年 | 85篇 |
1983年 | 54篇 |
1982年 | 72篇 |
1981年 | 47篇 |
1980年 | 28篇 |
1979年 | 27篇 |
1978年 | 28篇 |
1977年 | 30篇 |
1976年 | 21篇 |
1974年 | 18篇 |
1973年 | 22篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
121.
Franz Buchegger Mai Phan Denis Rivier Stephan Carrel Roberto S. Accolla Jean-Pierre Mach 《Journal of immunological methods》1982,49(2):129-139
A solid-phase enzyme immunoassay using both mouse monoclonal and goat polyclonal antibodies against carcinoembryonic antigen (CEA) was developed. The assay detects 0.6 to 1.2 ng of CEA per ml of serum and has 3 incubation steps which can be performed in 1 day. Polystyrene balls coated with polyclonal goat anti-CEA antibodies are first incubated with heat-extracted serum samples. Bound CEA is then detected by addition of mouse monoclonal antibodies, followed by goat IgG anti-mouse IgG1 coupled to alkaline phosphatase. Results with this enzyme immunoassay using monoclonal antibodiies (M-EIA) have been compared with those obtained by the conventional inhibition radioimmunoassay (RIA) using goat antiserum. Three hundred and eighty serum samples from 167 patients with malignant or non-malignant diseases and from 134 normal individuals with or without heavy smoking habits were analyzed by the 2 assays. Excellent correlation between the results of the 2 assays was obtained, but the M-EIA, using monoclonal antibodies from a single hybridoma, did not discriminate better than the conventional RIA between CEA produced by different types of carcinoma and between CEA associated with malignant or non-malignant diseases. Follow-up studies of several patients by sequential CEA determinations with the 2 assays showed that the M-EIA was as accurate as the RIA for the detection of tumor recurrences. 相似文献
122.
Negro R Mangieri T Coppola L Presicce G Casavola EC Gismondi R Locorotondo G Caroli P Pezzarossa A Dazzi D Hassan H 《Human reproduction (Oxford, England)》2005,20(6):1529-1533
BACKGROUND: Infertile women positive for thyroid antibodies suffer from a poor pregnancy/delivery outcome, although conflicting data have been published. Our objective was to investigate if levothyroxine (LT4) exerts any effect on pregnancy and/or delivery rates in thyroid peroxidase antibody (TPOAb)-positive (+) women undergoing assisted reproductive technologies. METHODS: Patients undergoing treatment were screened for TPOAb, thyroid-stimulating hormone (TSH) and free thyroxine (FT4). A total of 72 (15%) out of the 484 euthyroid women selected were TPOAb (+). These 72 patients were randomly divided into two groups: group A (n = 36) underwent LT4 treatment, group B (n = 36) placebo. Group C consisted of 412 women (85%) who were TPOAb negative (-). All patients received controlled ovarian stimulation. The endpoints of treatment were pregnancy rate, miscarriage rate and delivery rate. RESULTS: No differences in pregnancy rate were observed between the three groups. Miscarriage rate was higher in TPOAb (+) in comparison to TPOAb (-) [relative risk: 2.01 (95% CI = 1.13-3.56), P = 0.028]. CONCLUSIONS: The pregnancy rate is not affected either by presence of TPOAb or treatment with LT4. However, TPOAb (+) women show a poorer delivery rate compared to TPOAb (-). LT4 treatment in TPOAb (+) does not affect the delivery rate. 相似文献
123.
Effect of interferon-alpha therapy on epitope-specific cytotoxic T lymphocyte responses in hepatitis C virus-infected individuals. 总被引:4,自引:0,他引:4
Simona Vertuani Martina Bazzaro Guido Gualandi Fabiola Micheletti Mauro Marastoni Cinzia Fortini Alessandro Canella Michele Marino Roberto Tomatis Serena Traniello Riccardo Gavioli 《European journal of immunology》2002,32(1):144-154
The majority of hepatitis C virus (HCV)-infected individuals fail to resolve the infection and become chronically infected despite the presence of HCV-specific CTL responses directed to different HCV-derived peptide antigens. Only a minority of individuals is able to clear the virus by mounting efficient CTL responses early after acute infection, but at present it is not clear whether viral clearance is associated with CTL responses of defined specificity. To elucidate those responses associated with improvement of the disease, we analyzed CTL responses to 16 different HLA-A2-presented, HCV-derived epitopes in 12 chronically infected patients, 14 chronically infected patients treated with interferon-alpha, and in one patient with acute symptomatic disease. We show here that the majority of chronically infected individuals present CTL responses directed to an NS4-derived peptide antigen (amino acids 1789-1797). Treated patients presented stronger HCV-specific CTL responses and therapy-induced changes in CTL target choice. In particular, 13 out of 14 individuals responded to an NS3-derived epitope (amino acids 1073-1081). By longitudinal analysis we show that five individuals responding to IFN-alpha therapy with decreases in alanine aminotransferase levels presented a strong CTL activity directed to the NS3-derived epitope. One patient that spontaneously resolved the infection presented a generally strong CTL activity specific for HCV-derived epitopes with a dominant response to the NS3-derived peptide antigen. This suggests that CTL responses directed to this NS3-derived antigen may be beneficial for the control of HCV infection. Improvement of these responses may represent a therapeutic intervention in chronic HCV infection. 相似文献
124.
Alberto Bacchi-Modena Pierfrancesco Bolis Carlo Campagnoli Fiorenzo De Cicco Michele Meschia Francesco Pansini Roberto Pisati Gabriele Hüls 《Maturitas》1997,27(3):285-292
Objectives: To assess the efficacy and tolerability of a new matrix patch delivering 0.05 mg estradiol per day (Estraderm MX 50) in postmenopausal women with moderate to severe postmenopausal symptoms. Methods: A multicenter, double-blin, randomized, between-patient, placebo controlled trial in 109 postmenopausal women was carried out. Patches were applied twice weekly for 12 weeks. Patients were assessed at 4, 8 and 12 weeks of treatment. The primary efficacy variable was change from baseline in mean number of moderate to severe hot flushes (including night sweats) per 24 h during the last 2 weeks of treatment. Other variables included Kupperman Index, local and systemic tolerability. Plasma concentrations of estradiol (E2), estrone (E1) and estrone sulfate (E1S) were determined before and after treatment. Results: Estraderm MX was significantly superior to placebo (P < 0.001) in reducing mean number of moderate to severe hot flushes (including night sweats) per 24 h after 4, 8 and 12 weeks of treatment. The estimate of treatment group differences after 12 weeks was 4.2 hot flushes (95% confidence interval: 2.6–5.5). Estraderm MX also significantly reduced Kupperman Index at all time points compared to placebo (P < 0.001). Estraderm MX induced increases in mean E2, E1 and E1S plasma levels as expected (E2: baseline 2.7 pg/ml, 12 weeks 38.9 pg/ml; E1: baseline 18.8 pg/ml, 12 weeks 41.6 pg/ml; E1S: baseline 235.6 pg/ml, 12 weeks 765.1 pg/ml). Overall rates of adverse experiences were similar for Estraderm MX and placebo. The number of patients reporting skin irritation was low and similar in both groups. Conclusions: Estraderm MX 50, a new matrix patch, offers an effective and well tolerated dosage form for transdermal delivery of 0.05 mg E2 per day. 相似文献
125.
Meyer-Fernandes JR Saad-Nehme J Peres-Sampaio CE Belmont-Firpo R Bisaggio DF Do Couto LC Fonseca De Souza AL Lopes AH Souto-Padrón T 《Parasitology research》2004,93(1):41-50
In this work, we describe the ability of living epimastigotes of Trypanosoma cruzi to hydrolyze extracellular ATP. In these intact parasites, there was a low level of ATP hydrolysis in the absence of any divalent metal (2.42±0.31 nmol Pi/h×108 cells). ATP hydrolysis was stimulated by MgCl2, and the Mg-dependent ecto-ATPase activity was 27.15±2.91 nmol Pi/h×108 cells. The addition of MgCl2 to the extracellular medium increased the ecto-ATPase activity in a dose-dependent manner. This stimulatory activity was also observed when MgCl2 was replaced by MnCl2, but not by CaCl2 or SrCl2. The apparent Km for Mg-ATP2– was 0.61 mM, and free Mg2+ did not increase the ecto-ATPase activity. This ecto-ATPase activity was insensitive to the inhibitors of other ATPase and phosphatase activities. To confirm that this Mg-dependent ATPase was an ecto-ATPase, we used an impermeant inhibitor, DIDS (4, 4.diisothiocyanostylbene 2-2-disulfonic acid) as well as suramin, an antagonist of P2 purinoreceptors and inhibitor of some ecto-ATPases. These two reagents inhibited the Mg2+-dependent ATPase activity in a dose-dependent manner. A comparison among the Mg2+-ecto-ATPase activities of the three forms of T. cruzi showed that the noninfective epimastigotes were less efficient at hydrolyzing ATP than the infective trypomastigote and amastigote stages. 相似文献
126.
127.
128.
129.